Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agents antinéoplasiques - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinome, poumon non à petites cellules - agents antinéoplasiques - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tremelimumabum - solution à diluer pour perfusion - tremelimumabum 25 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.012 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1.25 ml. - hepatozelluläres karzinom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tremelimumabum - solution à diluer pour perfusion - tremelimumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.185 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml. - hepatozelluläres karzinom - biotechnologika

Canada - français - Health Canada

astrazeneca canada inc - trémélimumab - solution - 20mg - trémélimumab 20mg